{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:26:56Z","timestamp":1793287616021,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["Medicines360"],"award-info":[{"award-number":["Medicines360"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003358","name":"Gedeon Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AJOG Global Reports"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.xagr.2023.100266","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:05:32Z","timestamp":1695002732000},"page":"100266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The benefits of estetrol addition to drospirenone for contraception"],"prefix":"10.1016","volume":"3","author":[{"given":"Jean Michel","family":"Foidart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gemzell-Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Kubba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell D.","family":"Creinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulysse","family":"Gaspard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xagr.2023.100266_bib0001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/13625187.2022.2093850","article-title":"A novel estetrol-containing combined oral contraceptive: European expert panel review","volume":"27","author":"Gemzell-Danielsson","year":"2022","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.xagr.2023.100266_bib0002","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0889-8545(05)70169-8","article-title":"Health benefits of oral contraceptives","volume":"27","author":"Jensen","year":"2000","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.xagr.2023.100266_bib0003","first-page":"41","article-title":"Non-contraceptive benefits of oral hormonal contraceptives","volume":"11","author":"Schindler","year":"2013","journal-title":"Int J Endocrinol Metab"},{"key":"10.1016\/j.xagr.2023.100266_bib0004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1020084728544","article-title":"Noncontraceptive health benefits of oral contraceptives","volume":"3","author":"Kaunitz","year":"2002","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.xagr.2023.100266_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1995.tb31386.x","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity","volume":"761","author":"Muhn","year":"1995","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl3","key":"10.1016\/j.xagr.2023.100266_bib0007","first-page":"19","article-title":"Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone","volume":"7","author":"Oelkers","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.xagr.2023.100266_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2003.10.030","article-title":"Drospirenone, a progestogen with antimineralocorticoid properties: a short review","volume":"217","author":"Oelkers","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl3","key":"10.1016\/j.xagr.2023.100266_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/13697130500330382","article-title":"Pharmacology of different progestogens: the special case of drospirenone","volume":"8","author":"Sitruk-Ware","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.xagr.2023.100266_bib0010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/09513590701582323","article-title":"Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen","volume":"23","author":"Foidart","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.xagr.2023.100266_bib0011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/13625187.2020.1743828","article-title":"Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature","volume":"25","author":"Palacios","year":"2020","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.xagr.2023.100266_bib0012","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2015.07.014","article-title":"Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability","volume":"92","author":"Archer","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0013","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/aogs.13688","article-title":"Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill","volume":"98","author":"Palacios","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.xagr.2023.100266_bib0014","first-page":"1816","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"Oelkers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xagr.2023.100266_bib0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13625180008500387","article-title":"A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel","volume":"5","author":"Foidart","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.xagr.2023.100266_bib0016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/13625187.2022.2164186","article-title":"The drospirenone (DRSP)-only pill: clinical implications in the daily use","volume":"28","author":"Kubba","year":"2023","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.xagr.2023.100266_bib0017","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-200317050-00003","article-title":"The role of hormones and hormonal treatments in premenstrual syndrome","volume":"17","author":"B\u00e4ckstr\u00f6m","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.xagr.2023.100266_bib0018","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1358\/dot.2008.44.2.1191057","article-title":"Drospirenone\/ethinyl estradiol","volume":"44","author":"Rapkin","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.xagr.2023.100266_bib0019","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/13625187.2017.1336532","article-title":"Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control","volume":"22","author":"Apter","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.xagr.2023.100266_bib0020","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.contraception.2016.04.015","article-title":"Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA)","volume":"94","author":"Apter","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0021","first-page":"207","article-title":"Metabolism of 17-beta-oestradiol-4-14-C in early infancy","volume":"49","author":"Hagen","year":"1965","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"Suppl1","key":"10.1016\/j.xagr.2023.100266_bib0022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13697130802054078","article-title":"A new route of synthesis of estetrol","volume":"11","author":"Warmerdam","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.xagr.2023.100266_bib0023","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.3390\/jcm10235625","article-title":"Estetrol: a new choice for contraception","volume":"10","author":"Fruzzetti","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.xagr.2023.100266_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17512433.2022.2054413","article-title":"Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause","volume":"15","author":"G\u00e9rard","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.xagr.2023.100266_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40268-023-00419-5","article-title":"Estetrol: from preclinical to Clinical Pharmacology and advances in the understanding of the molecular mechanism of action","volume":"23","author":"G\u00e9rard","year":"2023","journal-title":"Drugs R D"},{"key":"10.1016\/j.xagr.2023.100266_bib0026","unstructured":"NEXTSTELLIS (drospirenone and estetrol). FDA label, Mayne Pharma. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214154s000lbl.pdf. Accessed November 22, 2022."},{"key":"10.1016\/j.xagr.2023.100266_bib0027","unstructured":"Drovelis assessment report EMA\/212533\/2021. European Medicines Agency. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/drovelis-epar-public-assessment-report_en.pdf. Accessed January 31, 2023."},{"key":"10.1016\/j.xagr.2023.100266_bib0028","unstructured":"YAZ (drospirenone\/ethinyl estradiol). FDA label, Bayer Healthcare Pharmaceuticals Inc. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021676s012lbl.pdf. Accessed November 30, 2022."},{"key":"10.1016\/j.xagr.2023.100266_bib0029","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.contraception.2012.12.011","article-title":"Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment","volume":"87","author":"Stanczyk","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0002-9378(90)90577-T","volume":"163","author":"H\u00fcmpel","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.xagr.2023.100266_bib0031","unstructured":"Zoely (estradiol \/nomegestrol acetate). SmPC, Theramex Ireland Ltd. 2021. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zoely-epar-product-information_en.pdf. Accessed November 22, 2022."},{"issue":"Suppl1","key":"10.1016\/j.xagr.2023.100266_bib0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/13697130802073425","article-title":"Estetrol review: profile and potential clinical applications","volume":"11","author":"Coelingh Bennink","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.xagr.2023.100266_bib0033","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/jcem-53-1-69","article-title":"Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma","volume":"53","author":"Pugeat","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xagr.2023.100266_bib0034","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0960-0760(00)00168-0","article-title":"Interactions between human plasma sex hormone-binding globulin and xenobiotic ligands","volume":"75","author":"Hodgert Jury","year":"2000","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl1","key":"10.1016\/j.xagr.2023.100266_bib0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13697130701851814","article-title":"Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells","volume":"11","author":"Hammond","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.xagr.2023.100266_bib0036","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.steroids.2014.08.003","article-title":"Estrogen metabolites and breast cancer","volume":"99","author":"Santen","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.xagr.2023.100266_bib0037","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.steroids.2014.08.006","article-title":"Mechanisms of estrogen carcinogenesis: the role of E2\/E1-quinone metabolites suggests new approaches to preventive intervention\u2013a review","volume":"99","author":"Yager","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.xagr.2023.100266_bib0038","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0039","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/clinem\/dgac511","article-title":"Low thrombin generation in users of a contraceptive containing estetrol and drospirenone","volume":"108","author":"Morimont","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xagr.2023.100266_bib0040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17512433.2020.1783247","article-title":"Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception","volume":"13","author":"Chiara Del Savio","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.xagr.2023.100266_bib0041","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2019.10.005","article-title":"Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females","volume":"101","author":"Richter","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0042","unstructured":"SLYND (drospirenone). FDA label, Exceltis USA Inc. 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211367s000lbl.pdf. Accessed November 22, 2022."},{"key":"10.1016\/j.xagr.2023.100266_bib0043","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.contraception.2013.04.001","article-title":"The creeping Pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?","volume":"88","author":"Trussell","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0044","unstructured":"Slinda 4 mg film coated tablets. Exeltis Healthcare S.L. 2022. Available at: https:\/\/docetp.mpa.se\/LMF\/Slinda%20film-coated%20tablet%20ENG%20SmPC_09001bee 807a7be0.pdf. Accessed November 22, 2022."},{"key":"10.1016\/j.xagr.2023.100266_bib0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","volume":"104","author":"Creinin","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0046","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1471-0528.16840","article-title":"Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia","volume":"129","author":"Gemzell-Danielsson","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.xagr.2023.100266_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.conx.2020.100020","article-title":"A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24\/4-day regimen","volume":"2","author":"Kimble","year":"2020","journal-title":"Contracept X"},{"key":"10.1016\/j.xagr.2023.100266_bib0048","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0049","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.contraception.2009.01.016","article-title":"Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24\/4-day regimen","volume":"80","author":"Hern\u00e1di","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0050","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.3390\/jcm11154634","article-title":"Bleeding patterns of oral contraceptives with a cyclic dosing regimen: an overview","volume":"11","author":"Archer","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.xagr.2023.100266_bib0051","unstructured":"NDA\/BLA Multi-disciplinary review and evaluation. Food and Drug Administration. 2019. Available at: https:\/\/www.fda.gov\/media\/129539\/download. Accessed October 14, 2022."},{"key":"10.1016\/j.xagr.2023.100266_bib0052","unstructured":"Medical review Yaz (NDA 21\u2013676). Food and Drug Administration. 2006. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021676s000_MEDR_pt1.pdf. Accessed May 25, 2022."},{"key":"10.1016\/j.xagr.2023.100266_bib0053","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12905-020-01080-9","article-title":"Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24\/4 regime","volume":"20","author":"Palacios","year":"2020","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.xagr.2023.100266_bib0054","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/13625187.2021.1957094","article-title":"Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 \u00b5g: a double-blind, double-dummy, prospective, randomised study","volume":"26","author":"Palacios","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.xagr.2023.100266_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.contraception.2021.01.001","article-title":"Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone","volume":"103","author":"Klipping","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0056","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.contraception.2022.10.004","article-title":"Tolerability and safety of the estetrol\/drospirenone combined oral contraceptive: pooled analysis of two multicenter, open-label phase 3 trials","volume":"116","author":"Chen","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0057","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xagr.2023.100266_bib0058","first-page":"463","article-title":"Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives","volume":"20","author":"Mawet","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.xagr.2023.100266_bib0059","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.contraception.2008.01.016","article-title":"Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study","volume":"78","author":"Gargano","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231856","article-title":"Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg","volume":"15","author":"Palacios","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.xagr.2023.100266_bib0061","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/09513590.2021.1963432","article-title":"Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24\/4 regimen and comparison to 0.075 mg desogestrel","volume":"37","author":"Regidor","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.xagr.2023.100266_bib0062","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.contraception.2022.07.009","article-title":"Pooled efficacy results of estetrol\/drospirenone combined oral contraception phase 3 trials","volume":"116","author":"Jensen","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0063","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/AOG.0000000000005155","article-title":"Combined oral contraceptive adherence and pregnancy rates","volume":"141","author":"Creinin","year":"2023","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xagr.2023.100266_bib0064","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.contraception.2022.07.010","article-title":"Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol\/drospirenone on bleeding patterns in healthy women","volume":"116","author":"Kaunitz","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0065","doi-asserted-by":"crossref","first-page":"e2990","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.xagr.2023.100266_bib0066","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2020.08.006","article-title":"Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled \u201cEstrogen and thrombosis: a bench to bedside review\u201d (Thrombosis Research 192 (2020) 40\u201351)","volume":"193","author":"Morimont","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.xagr.2023.100266_bib0067","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.contraception.2007.11.014","article-title":"Ovulation inhibition by estetrol in an in vivo model","volume":"77","author":"Coelingh Bennink","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0068","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/13697137.2022.2139599","article-title":"Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women","volume":"26","author":"Douxfils","year":"2023","journal-title":"Climacteric"},{"key":"10.1016\/j.xagr.2023.100266_bib0069","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJM199305273282108","article-title":"Hormonal contraception","volume":"328","author":"Baird","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xagr.2023.100266_bib0070","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.contraception.2011.04.009","article-title":"Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide","volume":"84","author":"Endrikat","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0071","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.contraception.2015.01.008","article-title":"A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women","volume":"91","author":"Dinh","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0072","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10456-005-9003-z","article-title":"Progestogen only contraception and endometrial break through bleeding","volume":"8","author":"Smith","year":"2005","journal-title":"Angiogenesis"},{"key":"10.1016\/j.xagr.2023.100266_bib0073","first-page":"1499","article-title":"Managing adverse effects of hormonal contraceptives","volume":"82","author":"Grossman Barr","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.xagr.2023.100266_bib0074","series-title":"Oral contraceptive pills","author":"Cooper","year":"2023"},{"key":"10.1016\/j.xagr.2023.100266_bib0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jtha.2022.10.014","article-title":"Factor V Leiden-independent activated protein C resistance: communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee","volume":"21","author":"Moore","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.xagr.2023.100266_bib0076","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3109\/09513590.2016.1161743","article-title":"Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24\u202f+\u202f4 cycle with desogestrel 75 \u03bcg per day","volume":"32","author":"Regidor","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.xagr.2023.100266_bib0077","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1515\/cclm-2019-0471","article-title":"Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need","volume":"58","author":"Douxfils","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.xagr.2023.100266_bib0078","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","article-title":"Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol","volume":"95","author":"Kluft","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0079","article-title":"Hormonal therapies and venous thrombosis: estrogen matters! Res Pract","volume":"7","author":"Morimont","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.xagr.2023.100266_bib0080","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1600-0412.2012.01444.x","article-title":"Hormonal contraception and venous thromboembolism","volume":"91","author":"Lidegaard","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.xagr.2023.100266_bib0081","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.fertnstert.2016.09.027","article-title":"Combined hormonal contraception and the risk of venous thromboembolism: a guideline","volume":"107","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xagr.2023.100266_bib0082","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/AOG.0b013e3182a1741c","article-title":"Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive","volume":"122","author":"Archer","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xagr.2023.100266_bib0083","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.contraception.2019.02.001","article-title":"Segesterone acetate\/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation","volume":"99","author":"Gemzell-Danielsson","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0084","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2020.11.011","article-title":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results","volume":"103","author":"Nelson","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0010-7824(02)00537-1","article-title":"A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism","volume":"67","author":"Gaspard","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.xagr.2023.100266_bib0086","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beem.2012.09.004","article-title":"Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills","volume":"27","author":"Sitruk-Ware","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.xagr.2023.100266_bib0087","unstructured":"FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended July 2023). FSRH Clinical Effectiveness Unit. 2023. Available at: https:\/\/www.fsrh.org\/standards-and-guidance\/documents\/combined-hormonal-contraception\/."},{"key":"10.1016\/j.xagr.2023.100266_bib0088","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/j.1538-7836.2010.03953.x","article-title":"The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy","volume":"8","author":"Bagot","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.xagr.2023.100266_bib0089","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2008-0450","article-title":"Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women","volume":"93","author":"Canonico","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xagr.2023.100266_bib0090","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s00198-019-05103-6","article-title":"Bone health in estrogen-free contraception","volume":"30","author":"Hadji","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.xagr.2023.100266_bib0091","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.maturitas.2009.11.026","article-title":"The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction","volume":"65","author":"Cameron","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.xagr.2023.100266_bib0092","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1161\/CIRCULATIONAHA.105.539528","article-title":"Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus","volume":"112","author":"Wilson","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.xagr.2023.100266_bib0093","doi-asserted-by":"crossref","DOI":"10.1515\/jbcpp-2018-0184","article-title":"Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone","volume":"30","author":"Adeyanju","year":"2019","journal-title":"J Basic Clin Physiol Pharmacol"}],"container-title":["AJOG Global Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666577823001077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666577823001077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:21:01Z","timestamp":1763000461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666577823001077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2666577823001077"],"URL":"https:\/\/doi.org\/10.1016\/j.xagr.2023.100266","relation":{},"ISSN":["2666-5778"],"issn-type":[{"value":"2666-5778","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The benefits of estetrol addition to drospirenone for contraception","name":"articletitle","label":"Article Title"},{"value":"AJOG Global Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xagr.2023.100266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100266"}}